S49 Secondary Osteoporosis: When Good Hormones Go Bad

Program: Symposia
Clinical/Translational Session
Sunday, April 3, 2016: 8:15 AM-9:45 AM
Room 253 (BCEC)
Chair:
Elizabeth Shane, MD, Columbia University College of Physicians and Surgeons, New York, NY

Disclosures:
ES: Principal Investigator, Amgen, Principal Investigator, Lilly USA, LLC, Principal Investigator, Merck & Co..
8:15 AM
Kristy M Nicks, PhD, NIAMS, NIH Kelly Government Solutions, Bethesda, MD
Nothing to Disclose: KMN
8:45 AM
John Howard Duncan Bassett, PhD, Imperial College London, London, United Kingdom
Nothing to Disclose: JHDB
9:15 AM
Markus J Seibel, MD, PhD, FRACP, ANZAC Reseach Institute and Dept of Endocrinology & Metabolism, University of Sydney, Concord Medical School, Concord, Australia
Disclosures:
MJS: Speaker, Aventis Pharmaceuticals, Speaker, Amgen.
See more of: Symposia

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire